| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 26 | 32.2x | 17.8x | Bottom tier | |
Growth | 56 | 10.1% | 7.1% | Around median | |
Quality | 67 | 11.7% | 4.5% | Top tier | |
Safety | 91 | 0.4x | 2.6x | Top tier | |
Capital Return | 53 | 0.58% | 2.12% | Around median | |
Momentum | 54 | 10.4% | 2.9% | Around median | |
Sentiment | 68 | 2 | 3 | Top tier |
Estimates — analyst targets and a simplified DCF, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Balchem Corp operates through three interconnected segments that sell specialized, value-added ingredients and solutions. The Human Nutrition & Health segment provides science-based nutrients, food ingredients, and formulation and application services, benefiting from demand for foods that are higher in protein and fiber and lower in sugar, and from products such as VitaCholine, K2VITAL, Optifolin+, and OptiMSM. The Animal Nutrition & Health segment sells encapsulated and rumen-protected nutrient technologies for the dairy industry, alongside products for monogastric animals, while the Specialty Products segment includes performance gases and plant nutrition.
In fiscal Q2 2026, Balchem generated record quarterly revenue of $284 million, up 11.2% year over year, and gross profit of $103.7 million at a gross margin of 36.5%, up 10 basis points. GAAP operating income was $59 million, up 15.1%, while net income reached a record $44.6 million, or $1.39 per diluted share, representing growth of 16.6% and 18.8%, respectively. Adjusted EBITDA also reached $78 million, with a margin of 27.4% and growth of 12.6%.
The Human Nutrition & Health segment was the largest driver in fiscal Q2 2026, with record revenue of $177 million, representing about 62% of consolidated revenue, and operating income of $42 million. The Animal Nutrition & Health segment generated revenue of $64 million and operating income of $5 million, while the Specialty Products segment recorded record revenue of $41 million and record operating income of $13 million. This mix reflects profitability primarily driven by Human Nutrition & Health, with stronger growth acceleration in Animal Nutrition & Health during the same period.
Automated analysis for informational purposes only — not investment advice.
The analyst consensus is “Buy,” with an average price target of $215 and identical highest and lowest targets of $215; this target is approximately 16.9% above the 52-week range high of $183.9. The target is supported by the record results and year-over-year adjusted EBITDA growth for twenty-eight consecutive quarters through fiscal Q2 2026, but the extent to which it exceeds the range high increases the valuation's sensitivity to any slowdown in volumes or margins. The absence of variation between the highest and lowest targets also makes the consensus range narrow and does not present alternative valuation scenarios within the provided data.
Figures in the text are as of 2026-08-30; the live price is shown at the top of the page.
Balchem generated record revenue of $284 million in fiscal Q2 2026, up 11.2%, while net income rose 16.6% to $44.6 million. All three segments grew, led by a 15% increase in Animal Nutrition & Health and a 10% increase in Human Nutrition & Health. The company also recorded its twenty-eighth consecutive quarter of year-over-year adjusted EBITDA growth, reaching $78 million at a margin of 27.4%.
The segment generated record revenue of $177 million in fiscal Q2 2026, representing about 62% of consolidated revenue of $284 million. Its operating income was $42 million, up 10.5%, while adjusted operating earnings reached $46 million. Its growth is based on nutrients, food ingredients, and solutions, in addition to branded products such as VitaCholine, K2VITAL, Optifolin+, and OptiMSM.
Segment revenue rose 15% to $64 million, with roughly half of the increase coming from volume and the other half from pricing. The ruminant business grew by about 20%, driven almost entirely by higher volumes as adoption of encapsulated and rumen-protected nutrients expanded. In Europe, anti-dumping duties in effect since late December 2025 or early January 2026 helped the monogastric business recover volumes and pricing.
Balchem had between 20 and 25 studies underway at any one time, according to the July 31, 2026 call. During fiscal Q2 2026, four significant studies were published, covering OptiMSM, K2VITAL, and VitaCholine, with the aim of expanding the scientific evidence customers use in their product claims. On the marketing side, the multichannel engagement model generated more than one billion consumer impressions during the approximately 18 months through July 31, 2026, with some campaigns targeting GLP-1 users and their snack and meal-replacement needs.
Net debt was $89 million and the net leverage ratio was 0.3 times as of June 30, 2026, with $63 million in cash on the balance sheet. The company generated $47 million in operating cash flow and $36 million in free cash flow during fiscal Q2 2026. It also increased its credit facility capacity to $650 million and extended its maturity to 2031, while repurchasing $29 million of shares during the same quarter and $114 million during the twelve months ended June 30, 2026.
Input costs associated with the conflict in the Middle East increased manufacturing costs in fiscal Q2 2026, despite mitigation measures successfully maintaining a gross margin of 36.5%. Part of the recovery in the European monogastric business depends on the competitive environment following the implementation of anti-dumping duties since late December 2025 or early January 2026. In addition, $150 million was drawn at a variable interest rate of approximately 4.5% as of June 30, 2026, while the analyst target of $215 assumes a level above the 52-week range high of $183.9.
